VFA
COLL icon

Values First Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Values First Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$565K Buy
17,086
+83
+0.5% +$3.51K 0.29% 92
2025
Q4 		$787K Sell
17,003
-582
-3% -$24.4K 0.41% 75
2025
Q3 		$615K Sell
17,585
-864
-5% -$30K 0.33% 83
2025
Q2 		$546K Buy
18,449
+1,804
+11% +$51.5K 0.3% 98
2025
Q1 		$497K Sell
16,645
-261
-2% -$7.98K 0.29% 95
2024
Q4 		$484K Sell
16,906
-1,506
-8% -$49.8K 0.27% 97
2024
Q3 		$711K Buy
18,412
+1,419
+8% +$50.6K 0.39% 69
2024
Q2 		$547K Buy
16,993
+1,057
+7% +$36.6K 0.33% 78
2024
Q1 		$619K Sell
15,936
-17,929
-53% -$627K 0.36% 78
2023
Q4 		$1.04M Sell
33,865
-9,642
-22% -$242K 0.63% 47
2023
Q3 		$972K Buy
43,507
+6,557
+18% +$150K 0.63% 46
2023
Q2 		$794K Buy
36,950
+7,325
+25% +$166K 0.48% 62
2023
Q1 		$711K Sell
29,625
-18,003
-38% -$477K 0.45% 65
2022
Q4 		$1.1M Buy
47,628
+2,193
+5% +$44.2K 0.77% 44
2022
Q3 		$728K Sell
45,435
-2,652
-6% -$46.8K 0.52% 64
2022
Q2 		$852K Buy
48,087
+2,474
+5% +$41.6K 0.61% 54
2022
Q1 		$929K Buy
45,613
+3,301
+8% +$62.4K 0.59% 54
2021
Q4 		$790K Buy
42,312
+539
+1% +$10.5K 0.47% 70
2021
Q3 		$825K Buy
41,773
+4,551
+12% +$98.4K 0.53% 63
2021
Q2 		$880K Buy
37,222
+4,325
+13% +$99.9K 0.6% 58
2021
Q1 		$780K Sell
32,897
-6,142
-16% -$146K 0.58% 62
2020
Q4 		$782K Buy
39,039
+7,798
+25% +$152K 0.62% 57
2020
Q3 		$650K Buy
31,241
+6,932
+29% +$125K 0.6% 58
2020
Q2 		$425K Sell
24,309
-36
-0.1% -$705 0.42% 82
2020
Q1 		$398K Sell
24,345
-15,254
-39% -$315K 0.48% 68
2019
Q4 		$815K Buy
+39,599
New +$660K 0.79% 49

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Values First Advisors's COLL Position: Q1 2026 in Review

Values First Advisors increased its Collegium Pharmaceutical (COLL) stake by 0.49% in Q1 2026, buying an estimated $3.51K and bringing the position to 17,086 shares worth $565K. The position accounts for 0.29% of the portfolio, ranked #92.

Values First Advisors first reported a position in COLL in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.1M in Q4 2022. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Values First Advisors held 17,086 shares of Collegium Pharmaceutical worth $565K as of Q1 2026.
  • Values First Advisors bought 83 Collegium Pharmaceutical shares in Q1 2026, an estimated $3.51K.
  • Collegium Pharmaceutical made up 0.29% of Values First Advisors's portfolio in Q1 2026, its #92 holding.
  • Values First Advisors first reported a position in Collegium Pharmaceutical in Q4 2019 and has held it in 26 quarters since.
  • Values First Advisors's Collegium Pharmaceutical position peaked at $1.1M in Q4 2022.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Values First Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.